Actively Recruiting
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
Led by Shenyang Sunshine Pharmaceutical Co., LTD. · Updated on 2026-02-09
96
Participants Needed
1
Research Sites
96 weeks
Total Duration
On this page
Sponsors
S
Shenyang Sunshine Pharmaceutical Co., LTD.
Lead Sponsor
S
Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.
CONDITIONS
Official Title
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 to 75 years
- Histologically or cytologically confirmed advanced or metastatic malignant tumors
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Expected survival of at least 3 months
- Signed informed consent form
You will not qualify if you...
- Known uncontrolled or symptomatic central nervous system metastatic disease
- Grade greater than 1 adverse events from previous anticancer therapy (except alopecia and fatigue)
- Inadequate organ or bone marrow function
- Pregnant or breastfeeding women
- Known allergies, hypersensitivity, or intolerance to SPGL008
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China, 400030
Actively Recruiting
Research Team
Y
yongsheng Li
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
14
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here